Perioperative Botulinum Toxin A in Large Ventral Hernia Repair

Rationale and Mechanism

Large and complex ventral hernias - particularly those with loss of domain (hernia volume/abdominal cavity volume ratio >20-25%) - present a major challenge: chronic lateral retraction and shortening of the oblique and transversus abdominis muscles reduces abdominal wall compliance, making primary fascial closure impossible even after component separation techniques.

Botulinum toxin A (BTA) works by blocking presynaptic acetylcholine release at the neuromuscular junction, producing temporary, reversible chemical denervation ("chemical component separation") of the lateral abdominal wall musculature - external oblique, internal oblique, and transversus abdominis. The result is flaccid paralysis with lateral muscle elongation and increased compliance, facilitating midline approximation without requiring formal myofascial releases.

Sabiston Textbook of Surgery, p. 1641

Patient Selection

BTA is considered for:

Large/giant incisional hernias (defect width typically ≥10 cm)
Loss-of-domain hernias where the hernia volume/abdominal cavity volume (VH/VAC) ratio is elevated
Cases where component separation alone is predicted to be insufficient
Patients undergoing planned abdominal wall reconstruction (AWR), particularly TAR or Rives-Stoppa with anticipated difficulty achieving fascial closure
As a "downstaging" strategy - some units use BTA alone (with retromuscular mesh) to avoid the need for component separation entirely in select patients

Contraindications include known hypersensitivity to BTA, neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS), pregnancy, and active infection at the injection site.

Injection Protocol

Timing

BTA is administered 4-6 weeks before surgery - this is the window in which maximal lateral muscle elongation occurs and persists. Muscle recovery begins around 3-4 months; operating within the 4-6 week window captures peak effect.

Technique

Ultrasound-guided injection into each of the three lateral muscle layers bilaterally
Typically performed as an outpatient procedure
The needle is advanced between fascial planes under real-time ultrasound guidance to target the external oblique, internal oblique, and transversus abdominis separately

Dosing (from consensus and published series)

The 2024 Spanish consensus proposal (Pous-Serrano et al., PMID 38342140) and published literature describe:

Total dose: 300-500 IU of onabotulinumtoxinA (Botox) or equivalent, divided across bilateral injections
Common approach: 100-150 IU per side per muscle layer, distributed across multiple injection points along the lateral abdominal wall (flank)
Some protocols use a single injection per muscle layer per side; others use 3-4 points per muscle per side

Measurable Effect

The 2023 systematic review by Dias et al. (PMID 37329437) showed an average lateral muscle elongation of 4.11 cm with low heterogeneity across studies - this is the morphological basis for improved midline closure.

Evidence: What Does BTA Actually Achieve?

The evidence base has matured considerably but remains mixed. Here is the current state:

Fascial Closure

A 2021 propensity-matched study (Deerenberg et al.) found BTA improved fascial closure rates (92% vs. 81%, p=0.036).
A subsequent ACHQC registry-based propensity-matched study found no difference in fascial closure (86% vs. 85.2%, p=0.934).
The 2025 meta-analysis of propensity-score matched studies (Florencio de Mesquita et al., PMID 39966195) - 6 studies, 851 patients - found no significant difference in fascial closure (OR 1.54, 95% CI 0.78-3.05, p=0.21), component separation requirement (OR 1.50, 95% CI 0.54-4.14), SSI/SSO, hernia recurrence, LOS, or operative time. Critically, Trial Sequential Analysis showed the required sample size for a definitive conclusion has not been reached.
The May 2025 meta-analysis specifically on giant incisional hernias (Mejía-Saavedra et al., PMID 40445418) - 5 studies - found no significant improvement in fascial closure (RR 0.95, 95% CI 0.90-1.01) or hernia recurrence (RR 1.02), but did find a significant reduction in postoperative complications (RR 0.66, 95% CI 0.50-0.88). LOS was not significantly reduced.

Combined BTA + Progressive Preoperative Pneumoperitoneum (PPP)

For true loss-of-domain hernias, BTA and PPP are often used together. The 2024 systematic review by Giuffrida et al. (PMID 38572390) - 7 studies, 217 patients - showed:

BTA given ~30 days before surgery, PPP started ~15 days before
Average VH/VAC ratio reduction of 7.6%
Only 18.4% required posterior component separation (PCS) or TAR - suggesting the combination avoids the most invasive release techniques in the majority
SSI 17.5%, SSO 26.2%, recurrence 5.9%
PPP complications in 25.6% (mostly minor; 2 hollow viscus perforations, 5 deaths in the entire literature)

Regulatory and Safety Note

BTA injection into the lateral abdominal wall is off-label in all jurisdictions. The FDA mandates a black box warning for all botulinum toxin products regarding the risk of systemic spread and, in extreme cases, death. Reported adverse events specifically in the hernia context are rare and mostly minor (local pain, transient dyspnea), but patients should be counseled and formal informed consent obtained. The 2024 Spanish consensus paper provides a template informed consent document.

Current Recommendations (Sabiston, 2024 edition)

"There is no high-quality objective evidence that BTA, which adds significant cost to the hernia repair, aids with fascial closure. At this time, the use of BTA in abdominal wall reconstruction should be limited to uses in a trial context."

Sabiston Textbook of Surgery, p. 1641

Most high-volume hernia centers use BTA selectively for their most complex cases (large defects with loss of domain, anticipated failure of fascial closure without adjuncts) while acknowledging the limited RCT data. Tissue expanders and PPP remain complementary options when soft tissue coverage is the limiting factor.

Summary Table

Parameter	Details
Mechanism	Temporary chemical denervation of external oblique, internal oblique, transversus abdominis
Timing	4-6 weeks preoperatively
Dose	300-500 IU onabotulinumtoxinA, bilateral US-guided injection
Targets	All 3 lateral muscle layers bilaterally
Measurable effect	~4 cm lateral muscle elongation
Fascial closure	No consistent significant benefit in matched studies
Postoperative complications	Significant reduction (RR 0.66) in giant hernia series
Hernia recurrence	No significant benefit in current pooled data
Combined with PPP	Reduces need for invasive component separation (~18% required TAR/PCS)
FDA status	Off-label; black box warning for systemic spread
Current guidance	Limited to trial context or highly complex loss-of-domain cases

Key References

Florencio de Mesquita C et al. Hernia 2025 - meta-analysis, PSM studies, PMID 39966195
Mejía-Saavedra Y et al. Hernia 2025 - meta-analysis, giant incisional hernias, PMID 40445418
Dias ERM et al. Hernia 2023 - systematic review + meta-analysis, PMID 37329437
Giuffrida M et al. J Abdom Wall Surg 2024 - BTA + PPP in loss of domain, PMID 38572390
Pous-Serrano S et al. Cir Esp 2024 - consensus proposal on dosing/technique, PMID 38342140
Sabiston Textbook of Surgery (2024 ed.), Chapter on Preoperative Adjuncts for Ventral Hernia Repair, p. 1641

This is a shared conversation. Sign in to Orris to start your own chat.